AstraZeneca, Ionis drug for rare nerve disease successful in late-stage trial

Delaware Business Now

Jun 22, 2022

Positive high-level results from a late-stage study of a drug for those with a rare hereditary nerve disease are expected to lead AstraZeneca to apply for regulatory approval. The…